SEC Comment Letter 0000000000-24-013879 to INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC.
Date: Dec. 17, 2024 · CIK: 0001567264 · Accession: 0000000000-24-013879
AI Filing Summary & Sentiment
File numbers found in text: 333-283797
Letter
December 17, 2024 Lewis Bender Chief Executive Officer Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484 Re:Intensity Therapeutics, Inc. Registration Statement on Form S-1 Filed December 13, 2024 File No. 333-283797 Dear Lewis Bender: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey Schultz
Show Raw Text
December 17, 2024
Lewis Bender
Chief Executive Officer
Intensity Therapeutics, Inc.
1 Enterprise Drive, Suite 430
Shelton, CT 06484
Re:Intensity Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 13, 2024
File No. 333-283797
Dear Lewis Bender:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey Schultz